Hernández-Gago, Yolanda <br/><br/>
Cost effectiveness of a protocol using palivizumab in preterm infants.  [electronic resource] 

 -  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria  Mar 2017 
 - 169-186 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2171-8695 
<br/><br/><label>Standard No.: </label>10.7399/fh.2017.41.2.10565  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiviral Agents--economics<br/>Bronchiolitis--etiology<br/>Cost-Benefit Analysis<br/>Female<br/>Humans<br/>Infant<br/>Infant, Newborn<br/>Infant, Premature<br/>Male<br/>Palivizumab--economics<br/>Respiratory Syncytial Virus Infections--complications<br/>Retrospective Studies